ML 349

Selective and reversible lysophospholipase 2 (LYPLA2) inhibitor CAS# 890819-86-0

ML 349

Catalog No. BCC5612----Order now to get a substantial discount!

Product Name & Size Price Stock
ML 349: 5mg $115 In Stock
ML 349: 10mg Please Inquire In Stock
ML 349: 20mg Please Inquire Please Inquire
ML 349: 50mg Please Inquire Please Inquire
ML 349: 100mg Please Inquire Please Inquire
ML 349: 200mg Please Inquire Please Inquire
ML 349: 500mg Please Inquire Please Inquire
ML 349: 1000mg Please Inquire Please Inquire
Related Products
  • PR-619

    Catalog No.:BCC3627
    CAS No.:2645-32-1
  • WP1130

    Catalog No.:BCC3686
    CAS No.:856243-80-6

Quality Control of ML 349

Number of papers citing our products

Chemical structure

ML 349

3D structure

Chemical Properties of ML 349

Cas No. 890819-86-0 SDF Download SDF
PubChem ID 16193817 Appearance Powder
Formula C23H22N2O4S2 M.Wt 454.56
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : 20 mg/mL (44.00 mM; Need ultrasonic)
Chemical Name (5,5-dioxo-4H-thieno[3,2-c]thiochromen-2-yl)-[4-(4-methoxyphenyl)piperazin-1-yl]methanone
SMILES COC1=CC=C(C=C1)N2CCN(CC2)C(=O)C3=CC4=C(S3)C5=CC=CC=C5S(=O)(=O)C4
Standard InChIKey YVIJPELUPZUEJX-UHFFFAOYSA-N
Standard InChI InChI=1S/C23H22N2O4S2/c1-29-18-8-6-17(7-9-18)24-10-12-25(13-11-24)23(26)20-14-16-15-31(27,28)21-5-3-2-4-19(21)22(16)30-20/h2-9,14H,10-13,15H2,1H3
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of ML 349

DescriptionSelective and reversible lysophospholipase 2 (LYPLA2) inhibitor (IC50 = 144 nM). Displays selectively over LYPLA1 and 20 other serine hydrolases (IC50 values are >3000 and >10,000 nM respectively).

ML 349 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

ML 349 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of ML 349

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.1999 mL 10.9996 mL 21.9993 mL 43.9986 mL 54.9982 mL
5 mM 0.44 mL 2.1999 mL 4.3999 mL 8.7997 mL 10.9996 mL
10 mM 0.22 mL 1.1 mL 2.1999 mL 4.3999 mL 5.4998 mL
50 mM 0.044 mL 0.22 mL 0.44 mL 0.88 mL 1.1 mL
100 mM 0.022 mL 0.11 mL 0.22 mL 0.44 mL 0.55 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on ML 349

The diagnosis of pancreatic mucinous cystic neoplasm and associated adenocarcinoma in males: An eight-institution study of 349 patients over 15 years.[Pubmed:28211072]

J Surg Oncol. 2017 Jun;115(7):784-787.

BACKGROUND: Per WHO, 2000 classification, pancreatic mucinous cystic neoplasms (MCN) are defined by presence of ovarian stroma, and are primarily located in the pancreatic body/tail of females. The incidence of MCN and associated malignancy in males, since, standardization of MCN diagnostic-criteria is unknown. METHODS: MCN resections from 2000 to 2014 at eight institutions of the Central-Pancreas-Consortium were included, and divided into early (2000-2007) and late (2008-2014) time-periods. Primary aim was to characterize MCN and associated adenocarcinoma/high-grade-dysplasia (AC/HGD) in males versus females over time. RESULTS: Of 1667 resections for pancreatic cystic lesions, 349 pts (21%) had MCNs: 310 (89%) female, 39 (11%) male. Patients were equally divided between early (n = 173) and late (n = 176) time-periods. MCN in male-patients decreased over time (early: 15%, late: 7%; P = 0.036), as did pancreatic head/neck location (early: 22%, late: 11%; P = 0.01). MCN-associated AC/HGD was more frequent in males versus females (39 vs. 12%; P < 0.001). The overall rate of MCN-associated AC/HGD remained stable (early: 17%, late: 13%; P = 0.4), and was identical in males (39%) over both time-periods. Males with AC/HGD had more LN-positive disease versus females (57 vs. 22%; P = 0.039). CONCLUSIONS: As the diagnostic-criteria of MCN have standardized over time, MCN diagnosis has decreased in males and head/neck location. Despite this, MCN-associated adenocarcinoma/high-grade dysplasia has been stable and remains high in males. Any male with suspected MCN, regardless of location, should undergo resection.

Description

ML349 is a potent and specific acyl protein thioesterase 2 (APT-2) inhibitor with a Ki of 120 nM. ML349 is also an inhibitor of LYPLA2 with an IC50 of 144 nM.

Keywords:

ML 349,890819-86-0,Natural Products,Phospholipase, buy ML 349 , ML 349 supplier , purchase ML 349 , ML 349 cost , ML 349 manufacturer , order ML 349 , high purity ML 349

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: